In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...
Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback